Back to search

Boston University

A comparison of riluzole and edaravone for the treatment of amyotrophic lateral sclerosis

Abstract

dc:description.abstract

The exact mechanism for the pathogenesis of amyotrophic lateral sclerosis (ALS) is not known. However, a number of causes have been suggested in contributing to the pathology of ALS, including oxidative stress, excitotoxicity, mitochondrial dysfunction, aberrant protein accumulation, imbalance in calcium homeostasis, and inflammatory responses. ALS is either sporadic or familial. A number of mutations in genes have been associated with the familial form: superoxide dismutase 1 (SOD1), transactive response DNA-binding protein (TARDBP), chromosome 9 open reading frame 72 (C9ORF72), and fused in sarcoma/translated in liposarcoma (FUS/TLS). In the United States, the two Food and Drug Administration (FDA)-approved drugs for the treatment of ALS are riluzole and edaravone. Riluzole participates in glutamatergic transmission and has been previously shown to decrease excitotoxicity. Edaravone is a radical scavenger that decreases the generation of reactive oxygen species (ROS). In this thesis, clinical trials and scientific studies involving riluzole and edaravone were analyzed to compare the efficacy of these two drugs. In clinical trials, riluzole appears to prolong life in the early stages of ALS, whereas edaravone appears to only slow symptom progression. Making a decision between these two medications involves considering how each one exerts its effects as well as the efficacy of each one in clinical trials.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2021

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Rodriguez, Mark
Advisors dc:contributor.advisor
  • Offner, Gwynneth D.
  • Spencer, Jean L.

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/43874

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Rodriguez, Mark. A comparison of riluzole and edaravone for the treatment of amyotrophic lateral sclerosis. masters thesis, Boston University, 2021. https://hdl.handle.net/2144/43874